Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Operating Leases (2021 - 2025)

Aligos Therapeutics' Operating Leases history spans 5 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 68.2% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, down 68.2%, while the annual FY2025 figure was $1.5 million, 68.2% down from the prior year.
  • Operating Leases reached $1.5 million in Q4 2025 per ALGS's latest filing, down from $2.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $11.3 million in Q4 2021 to a low of $1.5 million in Q4 2025.
  • Average Operating Leases over 5 years is $7.5 million, with a median of $8.5 million recorded in 2023.
  • Peak YoY movement for Operating Leases: increased 6.56% in 2022, then crashed 68.2% in 2025.
  • A 5-year view of Operating Leases shows it stood at $11.3 million in 2021, then fell by 18.48% to $9.2 million in 2022, then fell by 16.66% to $7.7 million in 2023, then plummeted by 37.47% to $4.8 million in 2024, then plummeted by 68.2% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Operating Leases are $1.5 million (Q4 2025), $2.4 million (Q3 2025), and $3.2 million (Q2 2025).